Wall Street brokerages expect Imperva Inc (NASDAQ:IMPV) to post sales of $91.18 million for the current quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Imperva’s earnings, with the highest sales estimate coming in at $92.00 million and the lowest estimate coming in at $90.48 million. Imperva reported sales of $78.40 million during the same quarter last year, which indicates a positive year-over-year growth rate of 16.3%. The business is scheduled to issue its next quarterly earnings report after the market closes on Thursday, February 8th.

According to Zacks, analysts expect that Imperva will report full-year sales of $91.18 million for the current year, with estimates ranging from $321.00 million to $322.64 million. For the next year, analysts anticipate that the firm will post sales of $377.49 million per share, with estimates ranging from $372.00 million to $383.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Imperva.

Imperva (NASDAQ:IMPV) last announced its earnings results on Wednesday, November 8th. The software maker reported $0.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.11. The company had revenue of $83.89 million for the quarter, compared to analyst estimates of $83.79 million. Imperva had a negative return on equity of 8.52% and a net margin of 3.04%. The firm’s quarterly revenue was up 22.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.08 earnings per share.

IMPV has been the topic of a number of research analyst reports. Zacks Investment Research raised Imperva from a “hold” rating to a “strong-buy” rating and set a $50.00 target price on the stock in a research report on Tuesday, October 24th. BidaskClub lowered Imperva from a “hold” rating to a “sell” rating in a research report on Wednesday, December 27th. Morgan Stanley reissued an “underweight” rating and issued a $39.00 target price on shares of Imperva in a research report on Thursday, November 9th. Wells Fargo & Co lowered Imperva from an “outperform” rating to a “market perform” rating in a research report on Monday, October 9th. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $47.00 target price (down previously from $50.00) on shares of Imperva in a research report on Thursday, November 9th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. Imperva has an average rating of “Hold” and a consensus target price of $51.86.

Several institutional investors have recently bought and sold shares of IMPV. SG Americas Securities LLC purchased a new stake in shares of Imperva during the third quarter worth $134,000. First Quadrant L P CA purchased a new stake in shares of Imperva during the third quarter worth $136,000. Ameritas Investment Partners Inc. increased its position in shares of Imperva by 18.7% during the second quarter. Ameritas Investment Partners Inc. now owns 2,940 shares of the software maker’s stock worth $141,000 after acquiring an additional 464 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its position in shares of Imperva by 26.2% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,177 shares of the software maker’s stock worth $201,000 after acquiring an additional 866 shares during the period. Finally, Amalgamated Bank purchased a new stake in shares of Imperva during the second quarter worth $206,000. 96.83% of the stock is currently owned by institutional investors and hedge funds.

Shares of Imperva (IMPV) traded up $0.30 during midday trading on Monday, reaching $44.20. The company’s stock had a trading volume of 254,200 shares, compared to its average volume of 331,508. The stock has a market capitalization of $1,500.00, a price-to-earnings ratio of 163.70 and a beta of 1.78. Imperva has a 52 week low of $37.17 and a 52 week high of $52.40.

TRADEMARK VIOLATION WARNING: This piece was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2018/01/22/91-18-million-in-sales-expected-for-imperva-inc-impv-this-quarter.html.

Imperva Company Profile

Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.

Get a free copy of the Zacks research report on Imperva (IMPV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.